The Influence of GSTA1 Polymorphism to the Response to Intravenous Cyclophosphamide Therapy in the Lupus Nephritis PatientsHong-Na Wang1, Xiao-Ye Zhu2, Ying Zhu2, Miao Zhao3, Yuan-Cheng Chen3, Jun Xue2*, Chuan-Ming Hao2, Yong Gu2 and Shan-Yan Lin2
- *Corresponding Author:
- Xue J
Department of Nephrology, Huashan Hospital
Fudan University, 12 middle Wulumuqi Road
Shanghai 200040, China
E-mail: [email protected]
Received date: March 23, 2016; Accepted date: April 25, 2016; Published date: April 29, 2016
Citation: Wang NH, Zhu XY, Zhu Y, Zhao M, Chen YC, et al. (2016) The Influence of GSTA1 Polymorphism to the Response to Intravenous Cyclophosphamide Therapy in the Lupus Nephritis Patients. Lupus Open Access 1:115. doi:10.4172/loa.1000115
Copyright: © 2016 Wang HN, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Variations of clinical response of cyclophosphamide (CTX) treatment in lupus nephritis (LN) could still be recognized. LN patients with a GSTA1mutation (CT heterozygous) had a risk of none-response (P=0.005). Pharmacokinetics data indicated that patients with a GSTA1 heterozygous variant had a lower exposure to 4-OHCTX compared to wild-type patients (P=0.023). And clinical efficacy was significantly related to higher exposure to 4- OH-CTX (P=0.038). In conclusion, LN patients with GSTA1 heterozygousgenotypes had poor CTX treatment response due to less exposure to activated 4-OH-CTX.